The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: A multi-centre observational study

Diabetic Medicine

Volumn 31, Issue 4, 2014, Pages 403-411

  Thong, K Y ^a   Mcdonald, T J ^b,c   Hattersley, A T ^b   Blann, A D ^a   Ramtoola, S ^d   Duncan, C ^e   Carr, S ^f,g   Adamson, K ^h   Nayak, A U ⁱ   Khurana, R ^j   Hunter, S J ^k   Ali, A ^d   Au, S ^g   Ryder, R E J ^a  

^a CITY HOSPITAL   (United Kingdom)

^b Peninsula National Institute for Health Research Clinical Research Facility Peninsula Medical School University of Exeter ^*  (United Kingdom)

^c ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^d ROYAL BLACKBURN HOSPITAL   (United Kingdom)

^e VICTORIA HOSPITAL   (United Kingdom)

^f ULSTER HOSPITAL   (United Kingdom)

^g Lisburn BT28 1JP   (United Kingdom)

^h ST JOHN'S HOSPITAL   (United Kingdom)

ⁱ NEW CROSS HOSPITAL   (United Kingdom)

^j NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^k ROYAL VICTORIA HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CREATININE; HEMOGLOBIN A1C; LIRAGLUTIDE;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; POSTPRANDIAL STATE; PROTEIN URINE LEVEL; SENSITIVITY ANALYSIS; TREATMENT RESPONSE;

AGED; C-PEPTIDE; CREATININE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INCRETINS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; TREATMENT OUTCOME;

EID: 84896117467     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12367     Document Type: Article

References (29)

1. Russell-Jones D, Gough S. Recent advances in incretin-based therapies. Clin Endocrinol (Oxf) 2012; 77: 489-499.
2. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009; 11: 26-34.
3. Norris SL, Lee N, Thakurta S, Chan BK. Exenatide safety and efficacy: a systematic review. Diabet Med 2009; 26: 837-846.
4. Stonehouse A, Walsh B, Cuddihy R. Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies. Diabetes Technol Ther 2011; 13: 1063-1069.
5. Wilding JPH, Hardy K. Glucagon-like peptide-1 analogues for type 2 diabetes. Br Med J 2011; 342: d410.
6. Novo Nordisk A/S. Victoza (Liraglutide Injection) Prescribing Information. Available at http://www.novo-pi.com/victoza.pdf Last accessed 8 April 2013
7. Amylin Pharmaceuticals. Byetta (Exenatide Injection) Prescribing Information. Available at http://documents.byetta.com/Byetta_PI.pdf Last accessed 8 April 2013
8. Garber AJ. Incretin effects on β-cell function, replication, and mass: the human perspective. Diabetes Care 2011; 34: S258-263.
9. Vilsbøll T, Brock B, Perrild H, Levin K, Lervang HH, Kølendorf K et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 2008; 25: 152-156.
10. Bunck MC, Cornér A, Eliasson B, Heine RJ, Shaginian RM, Taskinen MR et al. Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011; 34: 2041-2047.
11. Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycaemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 2011; 34: 1463-1468.
12. Raman VS, Mason KJ, Rodriguez LM, Hassan K, Yu X, Bomgaars L et al. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care 2010; 33: 1294-1296.
13. Horwitz DL, Starr JI, Mako ME, Blackard WG, Rubenstein AH. Proinsulin, insulin and C-peptide concentrations in human portal and peripheral blood. J Clin Invest 1975; 55: 1278-1283.
14. Horwitz DL, Rubenstein AH, Katz AI. Quantitation of human pancreatic beta-cell function by immunoassay of C-peptide in urine. Diabetes 1977; 26: 30-35.
15. Gjessing HJ, Matzen LE, Faber OK, Froland A. Fasting plasma C-peptide, glucagon-stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes. Diabetologia 1989; 32: 305-311.
16. Bowman P, McDonald TJ, Shields BM, Knight BA, Hattersley AT. Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with Type 2 diabetes. Diabet Med 2012; 29: 90-93.
17. Besser RE, Ludvigsson J, Jones AG, McDonald TJ, Shields BM, Knight BA et al. Urine C-peptide creatinine ratio is a non-invasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care 2011; 34: 607-609.
18. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53: 766-772.
19. McDonald TJ, Knight BA, Shields BM, Bowman P, Salzmann M, Hattersley AT. Stability and reproducibility of a single-sample urinary C-peptide/creatinine ratio and its correlation with 24-h urinary C-peptide. Clin Chem 2009; 55: 2035-2039.
20. Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, Rave K et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010; 33: 1509-1515.
21. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised control trial. Diabetologia 2009; 52: 2046-2045.
22. Thong KY, Jose B, Sukumar N, Cull ML, Mills AP, Sathyapalan T et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit. Diabetes Obes Metab 2011; 13: 703-710.
23. Rosenstock TR, Shenouda SK, Bergenstal RM, Buse JB, Glass LC, Heilmann CR et al. Baseline factors associated with glycaemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care 2012; 35: 955-958.
24. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009; 32: 84-90.
25. Iwao T, Sakai K, Sata M. Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes. J Diabetes Complications 2013; 27: 87-91.
26. Nielsen LR, Rehfeld JF, Pedersen-Bjergaard U, Damm P, Mathiesen ER. Pregnancy-induced rise in serum C-peptide concentrations in women with type 1 diabetes. Diabetes Care 2009; 32: 1052-1057.
27. Tomaschitz A, Ritz E, Kienrich K, Pieske B, März W, Boehm BO et al. Circulating dopamine and C-peptide levels in fasting non-diabetic hypertensive patients: the Graz Endocrine Causes of Hypertension study. Diabetes Care 2012; 35: 1771-1773.
28. Thomas NJ, Shields BM, Besser RE, Jones AG, Rawlingson A, Goodchild E et al. The impact of gender on urine C-peptide creatinine ratio interpretation. Ann Clin Biochem 2012; 49: 363-368.
29. Ahrén B, Pacini G. Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol 2004; 150: 97-104.